Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors

Molecular Cancer

Volumn 8, Issue , 2009, Pages

  Kohler, Corina ^a   Radpour, Ramin ^a   Barekati, Zeinab ^a   Asadollahi, Reza ^a   Bitzer, Johannes ^a   Wight, Edward ^a   Bürki, Nicole ^b   Diesch, Claude ^b   Holzgreve, Wolfgang ^c   Zhong, Xiao Y ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b Kantonsspital Liestal   (Switzerland)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELL NUCLEUS DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MITOCHONDRIAL DNA; PROGESTERONE RECEPTOR; HER2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BLOOD LEVEL; BREAST TUMOR; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PROTEIN ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; BLOOD; CASE CONTROL STUDY; CELL FREE SYSTEM; CELL NUCLEUS; COHORT ANALYSIS; DIFFERENTIAL DIAGNOSIS; GENETICS; HEALTH; LYMPH NODE; METABOLISM; METASTASIS; PATHOLOGY;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL NUCLEUS; CELL-FREE SYSTEM; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; DNA, MITOCHONDRIAL; FEMALE; HEALTH; HUMANS; LYMPH NODES; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 71049146803     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-105     Document Type: Article

References (36)

1. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006, 355(25):2631-9. 10.1056/NEJMoa055373, 17182988.
2. Antoniades CA, Barker RA. The search for biomarkers in Parkinson's disease: a critical review. Expert Rev Neurother 2008, 8(12):1841-52. 10.1586/14737175.8.12.1841, 19086880.
3. Chou YY, Lepore N, Avedissian C, Madsen SK, Parikshak N, Hua X. Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls. Neuroimage 2009, 46(2):394-410. 10.1016/j.neuroimage.2009.02.015, 2696357, 19236926.
4. Hartwell L, Mankoff D, Paulovich A, Ramsey S, Swisher E. Cancer biomarkers: a systems approach. Nat Biotechnol 2006, 24(8):905-8. 10.1038/nbt0806-905, 16900126.
5. Nicolini A, Tartarelli G, Carpi A, Metelli MR, Ferrari P, Anselmi L. Intensive post-operative follow-up of breast cancer patients with tumor markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer 2006, 6:269. 10.1186/1471-2407-6-269, 1684262, 17116247.
6. Martinez L, Castilla JA, Blanco N, Peran F, Herruzo A. CA 125, CA 15.3, CA 27.29, CEA, beta-hCG and alpha-fetoprotein levels in cyst fluid of breast macrocysts. Int J Gynaecol Obstet 1995, 48(2):187-92. 10.1016/0020-7292(94)02279-8, 7540567.
7. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M. Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumor Biol 2005, 26(6):281-93.
8. Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Bohm-Velez M. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA 2008, 299(18):2151-63. 10.1001/jama.299.18.2151, 2718688, 18477782.
9. Tseng LM, Yin PH, Chi CW, Hsu CY, Wu CW, Lee LM. Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer. Genes Chromosomes Cancer 2006, 45(7):629-38. 10.1002/gcc.20326, 16568452.
10. Wu TL, Zhang D, Chia JH, Tsao KH, Sun CF, Wu JT. Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. Clin Chim Acta 2002, 321(1-2):77-87. 10.1016/S0009-8981(02)00091-8, 12031596.
11. Zachariah RR, Schmid S, Buerki N, Radpour R, Holzgreve W, Zhong X. Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors. Obstet Gynecol 2008, 112(4):843-50.
12. Zanetti-Dallenbach R, Wight E, Fan AX, Lapaire O, Hahn S, Holzgreve W. Positive correlation of cell-free DNA in plasma/serum in patients with malignant and benign breast disease. Anticancer Res 2008, 28(2A):921-5.
13. Zanetti-Dallenbach RA, Schmid S, Wight E, Holzgreve W, Ladewing A, Hahn S. Levels of circulating cell-free serum DNA in benign and malignant breast lesions. Int J Biol Markers 2007, 22(2):95-9.
14. Wang Y, Liu VW, Xue WC, Cheung AN, Ngan HY. Association of decreased mitochondrial DNA content with ovarian cancer progression. Br J Cancer 2006, 95(8):1087-91. 10.1038/sj.bjc.6603377, 2360719, 17047655.
15. Mambo E, Chatterjee A, Xing M, Tallini G, Haugen BR, Yeung SC. Tumor-specific changes in mtDNA content in human cancer. Int J Cancer 2005, 116(6):920-4. 10.1002/ijc.21110, 15856456.
16. Zhong XY, Ladewig A, Schmid S, Wight E, Hahn S, Holzgreve W. Elevated level of cell-free plasma DNA is associated with breast cancer. Arch Gynecol Obstet 2007, 276(4):327-31. 10.1007/s00404-007-0345-1, 17431649.
17. Xia P, Radpour R, Zachariah R, Fan AXC, Kohler C, Hahn S, Holzgreve W, Zhong XY. Simultaneous quantitative assessment of circulating cell-free mitochondrial and nuclear DNA by multiplex real-time PCR. Genetics and Molecular Biology 2009, 32(1):20-4.
18. Akobeng AK. Understanding diagnostic tests 3: Receiver operating characteristic curves. Acta Paediatr 2007, 96(5):644-7. 10.1111/j.1651-2227.2006.00178.x, 17376185.
19. Seefeld M, El Tarhouny S, Fan AX, Hahn S, Holzgreve W, Zhong XY. Parallel assessment of circulatory cell-free DNA by PCR and nucleosomes by ELISA in breast tumors. Int J Biol Markers 2008, 23(2):69-73.
20. El Tarhouny S, Seefeld M, Fan AX, Hahn S, Holzgreve W, Zhong XY. Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor. Cytokine 2008, 44(1):65-9. 10.1016/j.cyto.2008.06.008, 18691902.
21. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008, 14(9):985-90. 10.1038/nm.1789, 18670422.
22. Catarino R, Ferreira MM, Rodrigues H, Coelho A, Nogal A, Sousa A. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol 2008, 27(8):415-21. 10.1089/dna.2008.0744, 18694299.
23. Deligezer U, Eralp Y, Akisik EZ, Akisik EE, Saip P, Topuz E. Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer. Ann N Y Acad Sci 2008, 1137:175-9. 10.1196/annals.1448.010, 18837944.
24. Deligezer U, Eralp Y, Akisik EE, Akisik EZ, Saip P, Topuz E. Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy. Clin Chem Lab Med 2008, 46(3):311-7. 10.1515/CCLM.2008.080, 18254709.
25. Zhong XY, Hahn S, Holzgreve W. Prenatal identification of fetal genetic traits. Lancet 2001, 357(9252):310-1. 10.1016/S0140-6736(05)71754-2, 11214156.
26. Zhong XY, Holzgreve W, Hahn S. Risk free simultaneous prenatal identification of fetal Rhesus D status and sex by multiplex real-time PCR using cell free fetal DNA in maternal plasma. Swiss Med Wkly 2001, 131(5-6):70-4.
27. Zhong XY, Holzgreve W, Hahn S. Circulatory fetal and maternal DNA in pregnancies at risk and those affected by preeclampsia. Ann N Y Acad Sci 2001, 945:138-40.
28. Lo YM. Fetal DNA in maternal plasma: biology and diagnostic applications. Clin Chem 2000, 46(12):1903-6.
29. Deng Z, Wu G, Li Q, Zhang X, Liang Y, Li D. Noninvasive genotyping of 9 Y-chromosome specific STR loci using circulatory fetal DNA in maternal plasma by multiplex PCR. Prenat Diagn 2006, 26(4):362-8. 10.1002/pd.1422, 16566058.
30. Deng ZH, Li Q, Wu S, Li DC, Yang BC. [Application of 17 Y-chromosome specific STR loci in paternity testing]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008, 16(3):699-703.
31. Mizumachi T, Muskhelishvili L, Naito A, Furusawa J, Fan CY, Siegel ER. Increased distributional variance of mitochondrial DNA content associated with prostate cancer cells as compared with normal prostate cells. Prostate 2008, 68(4):408-17. 10.1002/pros.20697, 2268637, 18196528.
32. Selvanayagam P, Rajaraman S. Detection of mitochondrial genome depletion by a novel cDNA in renal cell carcinoma. Lab Invest 1996, 74(3):592-9.
33. Jiang WW, Rosenbaum E, Mambo E, Zahurak M, Masayesva B, Carvalho AL. Decreased mitochondrial DNA content in posttreatment salivary rinses from head and neck cancer patients. Clin Cancer Res 2006, 12(5):1564-9. 10.1158/1078-0432.CCR-05-1471, 16533782.
34. Lee HC, Hsu LS, Yin PH, Lee LM, Chi CW. Heteroplasmic mutation of mitochondrial DNA D-loop and 4977-bp deletion in human cancer cells during mitochondrial DNA depletion. Mitochondrion 2007, 7(1-2):157-63. 10.1016/j.mito.2006.11.016, 17280876.
35. Higuchi M. Regulation of mitochondrial DNA content and cancer. Mitochondrion 2007, 7(1-2):53-7. 10.1016/j.mito.2006.12.001, 1868520, 17320491.
36. Barrientos A, Casademont J, Cardellach F, Estivill X, Urbano-Marquez A, Nunes V. Reduced steady-state levels of mitochondrial RNA and increased mitochondrial DNA amount in human brain with aging. Brain Res Mol Brain Res 1997, 52(2):284-9. 10.1016/S0169-328X(97)00278-7, 9495550.